BTME = .40 CENT BREAK OUT ALERT READ...... | ABPH Message Board Posts


Advanced BioPhotonics Inc.

  ABPH website

ABPH   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message    Post Message    Post a Reply return to message boardtop of board
Msg  3 of 3  at  7/31/2007 1:01:11 AM  by

BREAK_OUT_ALERT


Buy

BTME = .40 CENT BREAK OUT ALERT READ......

BTME = .40 CENT BREAK OUT ALERT READ......

Welcome to BioTech MedicsTM !

[PINKSHEETS SYMBOL: BTME]

* Innovators in High Powered Therapeutic Medical Laser manufacturing and proprietary medical protocols.

** We are a group of Pain Management & Wellness Centers dedicated to helping you improve the quality of your life.

*** We have developed the patented SHBANTM SOLUTION. A non-alcohol based antimicrobial product that is odorless, safe (when used as directed) non-toxic and will not fade or bleach.

When were talking about small, unprofitable, biotech companies,

I rarely care about quarterly or even annual earnings.

What I care about is that the R&D programs stay on track

and that the products will make the company worth

a whole lot more in the future than it is today.

Quote by Charly Travers, The Motley Fool-January 12, 2005

Click on the links to learn more about us!

Thank you for clicking on our web site!

(c) BioTech Medics, Inc., 2004-2007 All Rights Reserved.

http://www.biotechmedics.com/index.html

24 Hour Toll Free Phone 1-800-200-2458

BioTech Medics Texas Headquarters - Urban Center - (Formerly Millennium Cntr)

222 West Las Colinas Blvd, 16th & 17th Floors

Irving, TX 75039 USA

Millennium Center is located in the heart of prestigious Las Colinas, on Highway 114 & O'Conner. Only 10 minutes East of the Dallas/Ft. Worth International Airport. BioTech Medics shares nearly 12,000 square feet on the 16th and Penthouse (17th floor) in the East tower in the Millennium Center with other tenants. Our offices feature panoramic views of the surrounding serene landscape, downtown Las Colinas and beautiful Lake Carolyn.

These offices are now a part of the Regus Group, PLC, a publically traded corporation on the London Stock Exchange (symbol: RGU). According to Mark Dixon, Chief Executive of Regus Group, PLC., "Many of the world's leading corporations-Nokia, AOL, Nationwide, GE, Boeing, IBM as well as small and emerging growth companies -are working with us to save money, increase flexibility and gain access to places to work virtually everywhere business gets done."

Office Interior 1 Our Board Room on the 16th Floor.

Reception area on the 16th Floor.

BioTech Medics commitment to diversity starts with our board of directors, our Advisory Board Members and extends throughout the organization.

KEITH A. HOUSER, Chairman and CEO of BioTech Medics, Inc., age 58, has over 32 years of both private and public corporate management experience. Mr. Houser has a B.A., degree from Malone College - Canton, Ohio (1970), with a major in Sociology/Social Work. He has continued his Masters Degree graduate studies at Hamma Graduate School-Wittenberg University, Springfield, Ohio (1970); & ELTS Graduate School-Capital University, Columbus, Ohio (1971), and is a graduate of CFNI, Dallas (1973). Mr. Houser has taken Continuing Education courses at UT Southwestern Medical Center-Dallas (1991-92).



Between 1990-1992, Mr. Houser was Director of SeniorPlus Adult Day Care in Dallas County, Texas. SeniorPlus was an approved US Veterans Administration outsourcing facility. Mr. Houser together with Dr. Charles Crane oversaw patients of varying ages. He worked daily with numerous licensed physicians, chiropractors, registered nurses, dieticians and therapists in caring for these patients. Mr. Houser was awarded the North Texas Small Business Administration (SBA) "Person of the Year Award" (1991) for this business.



Further, between 1994-1998, Mr. Houser advised an Arlington ophthalmic medical practice in marketing the newly FDA approved eye laser medical device for the LASIK procedure for the correction of nearsightedness. It was this experience with a laser that stirred Mr. Houser in seeking out further laser medical devices.



Previously, Mr. Houser has had an extensive background in radio and television and marketing commencing in 1966. He has worked for and/or managed/owned and/or operated radio and TV stations in Ohio, Indiana, Pennsylvania, New York, New Jersey and Arizona. As an entrepreneur Mr. Houser founded Family Television, Inc.. The TV station today currently has an estimated value of nearly $200 million. The independent commercial UHF television station was licensed by the Federal Communications Commission, Washington, DC: as WFTI-TV, Channel 54, Poughkeepsie/New York City, NY. The station was sold to TBN in 1982. Mr. Houser became an Advisor to the Board of Directors of the Financial News Network, 1982-84, (Formerly FNN, now CNBC). He has been an Advisory Board Member (1980-81) to Marist College, Dutchess Community College, and St. Marys College (all New York State Colleges)(1980-81). During Mr. Housers tenure at Marist College, the Lowell Thomas Award was created and a scholarship was established for promising students in broadcast journalism.



Mr. Houser in 1982 started Brocom Management, Inc., as a broadcast consulting and marketing company. As a broadcast consultant Mr. Houser was qualified as an Expert Witness before the Federal Communications Commission, Washington, D.C., in independent commercial television broadcasting, and a few state Supreme Courts, a State District Court (in radio), and has been featured in numerous broadcast publications.



In 2001 Mr. Houser created NutriHealth Marketing, now HaloLaser BioTherapy, LLC. HaloLaser became a distributor for healthcare products such as the National Safety Associates, Inc., (NAS) JuicePlus Products and the Freedom Quest, Inc., products. Then HaloLaser became the primary distributor for the NeuroLase Medical Laser Device. In December, 2004, HaloLaser merged with BioTech Medics.



Philanthropic projects have been a part of Mr. Housers career. He has chartered two non-profit charitable organizations since 1972, all with IRS 501(c)(3) Tax Exempt Status: EMCC, which has co-sponsored in collecting donations of approximately 1 million pounds annually since 1983 in the distribution of food, clothing and medical supplies and medical clinics in Mexico, the Philippines, East Timor, Indonesia; and to North American Indians. Lastly, he co-founded and was Secretary of CTS Services, Inc., Pittsburgh, Pennsylvania, an educational and private foundation that issued over $1.75 million in grants to various organizations over a 25-year period. DayStar Television Network which is headquartered in Texas is one such recipient.

CHARLES R. CRANE, MD, age 68, President of BioTech Medics, Inc., Director & Medical Director is a private practice physician, specializing in Physical Medicine & Rehabilitation and Electrodiagnostic Medicine. Dr. Crane is a Medical Consultant for ReviewMed, Shorman Solutions, Austin & Associates and Forte. He has previously served as a Physician Advisor to CENTRA Healthcare; Intracorp Medical Review; Concentra Healthcare; Medical Review; Texas Workers Compensation Fund; Texas Medical Foundation, PRO.

Dr. Crane has also served as Physician Consultant for the Texas Workers Compensation Insurance Fund-Treatment Preauthorization. He currently serves the Texas Workers Compensation Commission, Designated Doctor-Dispute Resolution. His current Hospital Affiliation is with Doctors Hospital, Dallas. He has held previous positions with: PRO Reviewer, Utilization Review Texas Medical Foundation; Medical Director In-Patient Rehabilitation; Baylor Medical Center, Garland; Consultant Rehabilitation for South Arlington Medical Center, Arlington, Texas; Consultant Rehabilitation, Navarro Regional Hospital, Corsicana, Texas; Consultant Rehabilitation, Shannon Medical Center, San Angelo, Texas; Consultant Rehabilitation, Northeast Community Hospital, Director of Electromyography (1978-1985); Doctors Hospital, Dallas, Texas; Medical Director, Department of Physical Medicine and Rehabilitation (1974-1978) Medical City Dallas; Medical Coordinator, Rehabilitation Services (1972-1974) Baylor University Medical Center, Dallas, Texas; Associate Director, Department of Physical Medicine and Rehabilitation (1968-1974); Baylor University Medical Center Dallas, Texas; Director of Residency Training, Physical Medicine and Rehabilitation (1970-1974).



Dr. Crane holds a B.S. degree in Biological Sciences from Southern Methodist University (1960); and is a graduate of the University of Texas Southwestern Medical School, M.D. (1964). His Physical Medicine and Rehabilitation Residency was at Baylor University Medical Center, Dallas, Texas (1965-1968). Dr. Crane holds a Texas medical license (1594 D) since August 1, 1964. He is board certified by the American Board of Physical Medicine and Rehabilitation, Board Certification (748) since June 1970 and by the American Board of Electrodiagnostic Medicine, Board Certification (0239) since March 18, 1989. He is a professional member of the following organizations: Dallas County Medical Society, Texas Medical Association, American Medical Association, Southern Medical Association, American Academy of Physical Medicine and Rehabilitation, Texas Society of Physical Medicine and Rehabilitation, DFW Society of Physical Medicine and Rehabilitation, Metroplex Spine Society, American Association of Electromyography and Electrodiagnosis, American College of Occupational & Environmental Medicine & the American College of Physician Executives.



Kim Peralta-Jacobs, D.C., Age 43, BioTech Medics Director, Secretary & Chiropractor. Dr. Jacobs is a 1991 pre-med graduate of Donnelly College, Kansas City. She is a 1995 graduate of Cleveland Chiropractic College, Kansas City, Mo.; and a recipient of the John L. Lorenta award 1993 of Excellence. Additionally, Dr. Jacobs has a B.S. degree from Park College, Parkville, MO, (cum laude) in Nutrition (2000). Dr. Jacobs is a Member of the American Business Womens Association, Kansas City, Mo. Dr. Jacobs has operated a private practice in Overland Park, Kansas since 1997.



James Nairne, Age 57, Chief Financial Officer. Mr. Nairne has prior medical laser experience as Managing Partner of Medical Laser Therapeutics, L.P. He also has extensive prior venture capital experience as the Managing Director of Venture Capital for BP Capital, LP, the investment arm of T. Boone Pickens and an Investment Partner with Best, Patterson & Crothers, Ltd.

Mr. Nairne has over 32 years experience as an accountant. He is a member of the Canadian Institute of Chartered Accountants and the Institute of Chartered Accountants of Manitoba, Canada.



Tanvir A. Khandaker, M.D., Director. Dr. Khandaker is President and Managing Director of Khandaker Partners & Co New York. Dr. Khandaker was previously associated in academic research at Harvard Medical School and affiliated Brigham & Women's and Massachusetts General Hospitals. Prior to starting Khandaker Partners & Co., Dr. Khandaker had served as consultant to various investment banks and Equity groups. From 1999-2000, he was an adjunct faculty at Fisher College, Boston. From 1997-1998 Dr. Khandaker participated in clinical trials at Mount Sinai Hospital, New York City. Dr .Khandaker has researched and completed analysis on over a thousand smallcap publicly traded and late stage private companies in various sectors.

Dr. Khandaker received his M.D., (Diploma in Medicine) from the distinguished Mitford Medical College, Dhaka, affiliated with Royal College of London. A national board scholar, he graduated with distinction in 1995. He was a practicing physician in internal medicine. Dr. Khandaker enjoys sports and was captain of the medical school soccer team. Dr. Khandaker is an active member of AAPI (American Association of Physicians of Indian Origin).

Home Co History Management Advisory Board Laser Contact Us Laser FAQS Testimonies Investor Info Mission Site Terms Arthritis News! Litigation HQ Offices Medical Clinics SHBAN SOLUTION New Press Releases Old Press Releases L I N K S


When were talking about small, unprofitable, biotech companies,

I rarely care about quarterly or even annual earnings.

What I care about is that the R&D programs stay on track

and that the products will make the company worth

a whole lot more in the future than it is today.

Quote by Charly Travers, The Motley Fool-January 12, 2005



Executive Summary



Good News....BTME's initial R&D is complete, products are patented & manufactured, have clearances and ready to distribute.



FORTUNE-SMALL BUSINESS MAGAZINE

The FSB 100 Americas Fastest-Growing Small Companies

#1-in Annual Ranking - HEALTHCARE



Overview: Healthcare is one of the top 5 issues facing the world today. BTME is at the forefront in the USA in a worldwide trend in the healthcare industry in the use of photobiostimulation (laser therapy) as a non-surgical, non-invasive, alternative means to reduce and/or eliminate muscle and joint pain and traumatic suffering from pain relating to other physical ailments.

BTME plans to manage and/or operate affiliated Pain Management & Wellness Centers in major cities of the USA and in key locations around the world. BTME features a HIGH POWERED proprietary therapeutic medical laser device which has FDA Clearance for treating the entire body to reduce or eliminate muscle, skeletal or arthritic pain.

The Company also has exclusively patented SHBAN antimicrobial anti-viral products. The Company conducted SHBAN solution tests as a non-hazardous topical anti-viral Avian Bird Flu disinfectant. The tests were successful and the Company is poised to explode with worldwide sales of its patented SHBAN products.



TIME MAGAZINE QUOTE:

Demand for Pain Management centersis soaringthe need simply cannot be met. Patients will have to heed the lessons of Vioxx and Celebrex and refuse to settle for prescription pad medicine Claudia Wallis

The Right & Wrong Way to Treat Pain



Highlight: PAIN MANAGEMENT IS A $1 TRILLION WORLDWIDE INDUSTRY.

Aging Americans and Europeans have placed a demand upon medical practitioners to provide a quick, safe means of treating pain in patients without unnecessary surgery or drugs. BTME will be able to glean from the huge Pain Management industry hundreds of millions of revenue annually. The Companys Medical Lasers Patented proprietary technology offers one of the most powerful Class IIIB FDA cleared array of wavelength spectrum (frequency) for a therapeutic medical laser in the world. Therapeutic non-invasive light therapy provides a means of treatment of pain for various human physical ailments such as arthritis, carpal tunnel syndrome, backache, sprained ankle, shoulder and neck stiffness, whiplash, tennis elbow, a pulled muscle, TMJ and 70 other ailments.



Over 10 years in research and development have already been spent on the development and design of the Therapeutic Medical Lasers used by BTME. Further the Lasers may be used for minor pain and stiffness associated with arthritis or muscle spasm. The devices may temporarily increase blood circulation and may be used to promote relaxation of muscle tissue.



Strategy: The Company with its proprietary Therapeutic Medical Laser technology plans on opening, operating or managing Pain Management & Wellness Centers in the top 100 markets in the USA covering over 74% of the US population; plus various locations worldwide. The BioTech Pain Management & Wellness Centers will combine blood testing, proprietary nutrition products, education & exercise instruction to help each patient regain their strength, & well-being plus provide pain relief. The SHBAN Solution is superior to hundreds of other antimicrobials because it is a non-toxic, non-bleaching, odorless disinfectant powerful enough to topically kill the Asian Bird Flu virus and most bacteria, fungus, mold and mildew without harming people, animals or the environment.

World braced for huge surge

in bird flu casesSunday February 4, 2007
The Observer

BTME'S PATENTED PROPRIETARY SHBANTM SOLUTION is poised for worldwide distribution. Should the Avian Bird Flu Virus continue to expand worldwide, SHBAN will be in great demand as a Hand Sanitizer and poultry farm sanitizer. SHBAN is long lasting (unlike alcohol based hand sanitizers) as it sprays a thin microscopic protective film on a person's hands to give hours of protection unless washed or rubbed off.



BioTech Medics, Inc., a 1997 Nevada public corporation

(Pinksheets symbol: BTME)

Total Authorized Common Shares : 500,000,000

Freely Trading Outstanding Common Shares (O/S): 14.119 million

(as of 06/22/2007) Source DTC

STOCK TRANSFER AGENT INFORMATION:

If you are an existing shareholder, attorney for a shareholder

registered brokerage firm or registered investment advisor;

Contact information for the company transfer agent:



Transfer OnLine

317 SW Alder Street, 2nd Floor

Portland OR 97204



Phone 503-227-2950 between 9AM-3PM-PST



or on the Web at www.transferonline.com



Note: The Transfer Agent may not be able to answer all investor questions.



General questions should be made to the BioTech Corporate Offices

at 972-274-5533 between 9AM-5PM-CST, during business days.



CERTIFIED CHARTERED ACCOUNTANTS:



BioTech Medics, Inc., has retained the Certified Public Accounting Firm of

MOORE & ASSOCIATES, LAS VEGAS, NEVADA.



TEXAS LEGAL COUNSEL FOR THE CORPORATION:



David F. Morris, Esq.

The Morris Law Firm

Dallas, Texas



Cautionary Language Regarding Forward-Looking Statements

Materials in this website may contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements give our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.

Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual results may vary materially, and there are no guarantees about the performance of BioTech Medics (BTMD) stock.

We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports to the SEC. In particular, you should read the discussion in the section entitled "Cautionary Factors That May Affect Future Results" in any report to the SEC, as it may be updated in our subsequent 10-Q and 8-K reports. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Other factors besides those listed there could also adversely affect the Company. That discussion is provided as permitted by the Private Securities Litigation Reform Act of 1995.



BIOTECH MEDICS, INC.





A Nevada Corporation





October 31, 2006



Information Provided Pursuant to

Rule 15c2-11 of the Securities and

Exchange Act of 1934, as Amended




DISCLOSURE STATEMENT



PURSUANT TO RULE 15c2-11



OF THE SECURITIES AND EXCHANGE ACT OF 1934





Current Information Regarding





BIOTECH MEDICS, INC.





The following information is provided to assist securities brokerage firms with due diligence compliance. This statement has not been filed with the NASD or any other regulatory agency. This information is set forth below as to BIOTECH MEDICS, INC. (referred to as We or the Company). We were incorporated on December 29, 1997, in the State of Nevada, as Summit Property Group, Inc. (hereinafter referred to as the Issuer). This information is provided for the purpose of providing information to broker-dealers trading in the securities of the Issuer in compliance with Rule 15c2-11(a)(5) of the Securities Exchange Act of 1934, as amended. The information provided follows the same numbering system found in the rule to wit:





Item 1. Exact Name of Issuer and Predecessor:



Issuer: BioTech Medics, Inc. from November 19, 2004 to

present



Previous Names: Corbel Holdings, Inc. from April 30, 2001 to

November 18, 2004



Summit Property Group, Inc. from December 29,

1997 to April 29, 2001



Item 2. Address of Issuers Principal Executive Offices:



Corporate Services of Nevada

507 North Division Street

Carson City, NV 89703

Telephone No.: (972) 274-5533

Facsimile No.: (972) 692-5441

Website Address: www.biotechmedics.com







Item 3. State and Date of Incorporation:



We were incorporated on December 29, 1997, in the State of Nevada.



Item 4. Exact Title and Class of Security:



We are currently authorized to issue two classes of stock, common stock and preferred stock. The CUSIP for our common stock is 090699109. Our common stock has only been quoted on the Pink Sheets on an unsolicited basis since it initiated trading on the Pink Sheets. Our current stock symbol is BTMD. Pink Sheets has discontinued the display of quotes on pinksheets.com for our common stock until adequate current information is made available.



Our preferred stock does not have a CUSIP and is not publicly traded.



Item 5. Par Value or Stated Value of Security:



Our common stock has a par value of $0.001 per share.

Preferred Stock par value of $.001 per share.



Item 6. Number of Shares or Total Amount of the Securities Outstanding As of the End of the Issuers Most Recent Fiscal Quarter and Fiscal Year and any Offerings of Securities in the Last Two Years:



A. Number of Shares Outstanding



Common Stock



We are authorized to issue 500,000,000 shares of common stock, par value $0.001.



As of the date we provided information in response to this item, we had 253,331,933 shares of common stock issued and outstanding, held by approximately 4717 shareholders. Of those 253,331,933 shares of common stock, 110,585,857 were free trading.





Preferred Stock



We are authorized to issue 10,000,000 shares of preferred stock, par value $.001, the rights, privileges, and preferences of which may be set by the Board of Directors without further shareholder approval.



As of the date we provided information in response to this item, no shares of our preferred stock have been issued.



B. Offerings of Securities



Within the last two year periods ending on the date of our last fiscal year and as of the date of this Disclosure Statement, we have had the following offerings of our securities:



1. In December, 2004, the Company issued 17.25 million Pennsylvania Exempt 504 common shares to Hamilton Holding PA Corp and/or their assigns. The Company was to receive $1 million under a Promissory Note signed by Hamilton. However, the Company only received less than $73,000. The matter is in litigation in the 68th Texas Dist. Court in Dallas, Texas.



2. The Company issued in 2005 1 million Pennsylvania Exempt 504 Common shares to Mark Brummel and 5 million Pennsylvania Exempt 504 Common shares to Sean Meagan for the sum of $9690.00.



3. The Company issued 4,800,000 Texas Exempt 504 Common shares to Lone Star Equity Group in 2005 for $14,072.80.



4. The Company issued Pennsylvania Exempt 504 Common Shares to KRKA for $11,130.00 in 2005 as a part of the Hamilton issue in 1 above.



5. In 2005, the Company issued 765,306 Minn. Exempt 504 Common shares to Alliance Equities for $5,357. Other consideration was a part of this transaction to the Company legal counsel.



6. In 2006 the Company issued Minn. Exempt 504 Common Shares to Redwood for $34,500 for 7,428,571.



7. In 2006 the Company issued 1,000,000 Texas Exempt 504 Common Shares to Jarvis Adventures, Inc. for $5,000.



Item 7. Name and Address of Transfer Agent:



Transfer Online

317 SW Alder Street, 2nd Floor

Portland OR 97204

Telephone No. (503) 227-2950



Our transfer agent is registered under the Exchange Act.



Item 8. Nature of the Issuers Business:



A. Business Development



We were organized on December 29, 1997, to operate as a property owner and/or management service. On December 7, 2004, we acquired HaloLaser BioTherapy, LLC, and now focus on alternative medicine and medical devices for the twenty-first century.



Information concerning the following specific items is furnished to provide a more complete understanding of the issuers business development:



1. The form of organization of the Issuer;



We are a Nevada corporation.



2. The year that the Issuer (or any predecessor) was organized;



We were incorporated on December 29, 1997, in the State of Nevada, as Summit Property Group, Inc.



3. The Issuers fiscal year end date;



Our fiscal year end date is December 31.



4. Whether the Issuer (and/or any predecessor) has been in bankruptcy, receivership or any similar proceeding;



We have not been in bankruptcy, receivership or any similar proceeding.



5. Whether the Issuer has made any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets not in the ordinary course of business;



On December 7, 2004, we acquired all of the outstanding membership interests of HaloLaser BioTherapy, LLC in exchange for 65,000,000 shares of our common stock.



On February, we acquired substantially all of the assets of FHJ Scientific, Inc., in exchange for 1,250,000 shares of our common stock, restricted in accordance with Rule 144 and signed a promissory note.



6. Any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments;



None that have not been extended or re-negotiated.



7. Any change of control;



On December 7, 2004, we acquired all of the outstanding membership interests of HaloLaser BioTherapy, LLC in exchange for 65,000,000 shares of our common stock. The entire prior board

of directors resigned and the Company came under new management and a new board of directors. The Company will notify Pinksheets should there be a change in control.



8. Any increase in 10% or more of the same class of outstanding equity securities;



On December 7, 2004, BTMD acquired all of the outstanding membership interests of HaloLaser BioTherapy, LLC in exchange for 65,000,000 shares of our common stock. At the time this did not constitute an increase greater than 10% of outstanding equity securities. Through the issuance of 504 stock in 2005 and 2006, this did constitute a greater than 10% increase or more of the same class of outstanding equity securities (see 6.B 1-7 above).



9. Describe any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off or reorganization;



On December 7, 2004, we acquired all of the outstanding membership interests of HaloLaser BioTherapy, LLC in exchange for 65,000,000 shares of our common stock. The Company issued a press release advising that the board of directors had issued a Resolution that the Company would not have a stock split during the first 12 months of operation under the new management.



On December 17, 2004, the Company acquired all of the common stock of Charles R. Crane MD & Associates, Inc., for 1,250,000 common shares and a promissory note for $1.25 million.



On March 18, 2005, the Company acquired the four (4) US Letters of Patent from FHJ Scientific for 1,250,000 common shares and a promissory note for $1.25 million.



10. Any delisting of the Issuers securities by any securities exchange or NASDAQ or deletion from the OTC Bulletin Board;



Our securities have not been de-listed by any securities exchange or NASDAQ or deleted from the OTC Bulletin Board.

11. Any current, past, pending or threatened legal proceedings or administrative actions either by or against the Issuer that could have a material effect on the Issuers business, financial condition, or operations. Any current, past or pending trading suspensions by a securities regulator.



The Company is in litigation with Adam Barnett, an individual of Miami, Florida. Legal Counsel have issued an opinion that this is a frivolous lawsuit which should have no adverse material effect on the Company.



B. Business of Issuer



We (1) sell one or more types of FDA cleared medical laser devices for the treatment of numerous symptoms and physical ailments of the human body associated with pain; (2) train and certify medical professionals in the use of our laser devices; (3) manage; market and affiliate with pain management and wellness medical centers in the United States; and (4) acquire US letters of patent and proprietary SHBAN Solution products and/or devices that compliment our goals of offering alternative medicine for the twenty-first century.



Information concerning the following specific items is provided to the extent material to an understanding of the issuer:



1. Issuers primary and secondary SIC Codes;



Primary: 8090 (Health & Allied Services)

Secondary: 62134 (Physical, Occupational Therapy)

Other: 62111 (Offices of Physician)

62151 (Medical & Diagnostic Labs)



2. If the Issuer has never conducted operations, is in the development stage or is currently conducting operations;



We are currently conducting operations.



3. State the names of any parent, subsidiary, or affiliate of the issuer, and describe its business purpose, its method of operation, its ownership, and whether it is included in the financial statements attached to this disclosure document;



The Company issues a combined financial statement with the income and expenses of the Charles R. Crane MD & Associates, Inc., Pain Management & Wellness Clinic in Dallas, Texas.



4. Effect of existing or probable governmental regulations on the business;



Not material to an understanding of the issuer.



5. An estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers;



$25,000 in Research & Development. The cost will be amortized over 5 years.



6. Costs and effects of compliance with environmental laws (federal, state and local);



The Company is required to comply with the Food & Drug Administration in the operation of medical lasers. The cost of compliance is less than $2,000 per year per laser. The medical lasers are declared non-hazardous by the FDA, therefore, no environmental laws will impact the Company.



7. Number of total employees and number of full time employees.



We have a total of 9 employees, 3 of which are full time employees



C. Investment Policies



Not Applicable.



Item 9. Nature of Products and Services Offered:



1. Principal products or services, and their markets;



The BioTech L3aser, an FDA 510(k) authorized medical laser, is one of the most powerful Class III B medical lasers in the United States. The BioTech L3asers patented proprietary protocols, frequency spectrum and high wattage provide the capabilities necessary to work the lasers healing effect to reduce or eliminate pain through biological stimulation over any area of the body.



The BioTech Pain Management & Wellness Centers will combine the proprietary BioTech L3aser medical laser device, blood testing, nutrition education with BioBody Products and lifestyle change programs to provide immediate aid to those in acute and chronic pain and help patients regain strength and well-being.



2. Distribution methods of the products or services;



The NeuroLase Medical Laser Device may only be sold to licensed medical practitioners (i.e. medical doctors, chiropractors, osteopaths, podiatrists and dentists). In some states an acupuncturist may be sold a laser.



3. Status of any publicly announced new products or services;

The Company is negotiating to sell a medical laser and affiliate with a Pain Management & Wellness Center in Panama City, Panama.



The Company is manufacturing its SHBAN Solution and offering it in 3 oz, 16oz, 32 oz, and 5 gallon quantities.



4. Competitive business conditions, the issuers competitive position in the industry, and methods of competition;



There are no known active US companies that have high powered Class III B laser devices similar to the NeuroLase or BioTech L3aser with the patented broad frequency range between 660nM and 1200nM and proprietary high power (up to 1200 mW) afforded the Company as a distributor and user of the BioTech L3aser under the rights granted to an end user of the spectrum.



Eight or more known US and foreign companies have sought FDA 510(k) marketing authorization for their laser therapy devices: Microlight, Erconia, Thor, Quantumm, Dynatronics, Laser Therapeutics and Avicenna. All have been granted FDA clearance for specified marketing, but six of the eight operate at 50% to 90% less power.



The other companies do not have the more powerful lasers because they do not have the patents necessary to have the prerequisite penetrating power and light spectrum for the laser as does the NeuroLase and BioTech L3aser to work quickly, successfully and properly on human muscle and tissue.



There are over 37 known worldwide laser manufacturers that produce flashlight size or small battery pack lasers that sell within a range of $ 750 to $49,995. Many low powered lasers are utilized on animals by veterinarians and have been upgraded for human use.



The few desktop flashlight lasers designed for physicians range in price from $2,500 to $24,999. They operate at one-tenth to one-half the power of the BioTech L3aser machines. Consequently, to accomplish what the BioTech L3aser does in 5 to 20 minutes over one-quarter of a human body would take a competitors laser over eight hours and numerous visits to the doctors office.



The SHBAN solution is protected by 4 US Letters of Patent owned by the Company. SHBAN is a very powerful antibacterial, anti-viral, anti-mold and anti-fungus topical disinfectant. It is superior because it is non-bleaching, odorless, colorless and non-toxic; therefore, when used as directed it is quick and safe to use around humans, animals and it does not harm the environment.



5. Sources and availability of raw materials and the names of principal suppliers;



The Company is a distributor for the NeuroLase 150C Medical

Laser Device manufactured by Spectrum Laser in Colorado Springs, CO. There are ample lasers available at any given time so that the Company may sell them.



6. Dependence on one or a few major customers;



We do not depend on one or a few major customers.



7. Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including their duration;



The distribution agreement with Spectrum Laser is for three (3) years and renewable. The relationship between Spectrum and the Company is on very good terms.



The SHBAN patents require that a net royalty be paid to the original patent holders via FHJ Scientific for the life of the patents.



The Company has filed with the US Patent & Trademark Office for trademarks on BioTech Medics, BioTech L3asers, SHBAN.

The Company has no labor contracts.



8. The need for any government approval of principal products or services. Discuss the status of any requested government approvals.



After a lengthy 10 year research and development period with the NeuroLase Medical Device the FDA granted a 510(k) marketing clearance in November, 2003. Clinical medical studies are currently being conducted utilizing the NeuroLase. No adverse rulings are expected by the FDA which would negatively impact the Company.



Item 10. Nature and Extent of Issuers Facilities:

The Company maintains its Nevada legal corporate offices at

Corporate Services of Nevada, 507 North Division Street,

Carson City, NV 89703


BTMDs Texas corporate headquarters is located at 222 West Las Colinas Boulevard, Suite 1650 East Tower, Irving, TX 75039. We entered into a lease agreement dated December 7, 2004 to lease the office space for our Texas corporate headquarters for a term of One (1) year, renewable annually.



The Company also has a lease with Northpoint IV at 12606 Greenville Avenue, Suite 105, Dallas, TX 75234 for the BioTech Medics Pain Management & Wellness Center with Dr. Charles R. Crane.



We do not own any property or properties for which the book value amounts to 10 percent or more of the total assets of the Company and its consolidated subsidiaries for the last fiscal year.


Item 11. Name of the Chief Executive Officer, Members of the Board of Directors, as well as Counsel, Accountant and Public Relations Consultant:



A. Officers, Directors and Advisors



1. Management



Our directors and officers are as follows:



Name Title



Keith A. Houser Chairman of the Board and Chief Executive Officer



Charles R. Crane President and Director



Kim Peralta Jacobs Secretary/Treasurer and Director





Keith A. Houser has been our Chairman of the Board and Chief Executive Officer since December 7, 2004. From 1994 to 1998, Mr. Houser advised Arlington Ophthalmology Association and David Kleiman, M.D. in the final stages of FDA approval of the eximer eye laser for the LASIK treatment of the correction of nearsightedness. In 2001, Mr. Houser founded and from 2001 to 2004, was president of NutriHealth Marketing, subsequently known as HaloLaser BioTherapy, LLC (Halo), which became the primary distributor for the NeuroLase Medical Laser Device and merged with BioTech Medics in December 2004. Mr. Houser has an extensive marketing background in radio and television broadcasting from 1966 through 2000. He has managed, owned and/or operated radio and television states from Phoenix, AZ to New York City. As of the date we provided information in response to this item, Mr. Houser has proxy authority for 145 million shares of BTMD common stock.



Charles R. Crane has been our President and Director since December 7, 2004. Over the past thirty years, Dr Crane has operated a private medical practice, specializing in Physical Medicine & Rehabilitation and Electromyograpy. In addition, he is currently a medical consultant for ReviewMed, Shorman Solutions, Austin & Associates and Forte. He is not currently a member of any other board of directors. As of the date we provided information in response to this item, he owned 3 million shares of BTMD common stock.



Kim Peralta Jacobs has been our Secretary/Treasurer and Director since December 7, 2004. Over the past ten years, Dr. Jacobs has operated a private chiropractic practice in Overland Park, Kansas. She is not currently a member of any other board of directors. As of the date we provided information in response to this item, Dr. Jacobs owned approximately 507,000 shares of BTMD common stock.



2. General Partners;



None.



3. Investment Banker;



None.



4. Promoters;



Goldstake Enterprises, LLC, Sacramento, CA.



5. Control Persons;



Please see the above disclosure for Keith A. Houser, Charles R. Crane and Kim Jacobs.





6. Legal Counsel;



Our corporate legal counsel is:

David Morris, Esq.

The Morris Law Firm

Dallas, Texas



and securities legal counsel is

The Lebrecht Group

Brian Lebrecht, Esq.

S. Jordan, Utah



7. Accountant or Auditor;



Our independent certified public accountant is Michael Morris, CPA. His telephone number is 702-253-7511 in Las Vegas, NV.





8. Public Relations Consultant.



No.



B. Legal/Disciplinary History



To the best of our knowledge, none of the foregoing persons has, during the last five years, been the subject of the following except as follows:



1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);



No.



2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such persons involvement in any type of business, securities, commodities, or banking activities;



No.



3. A finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated;



No.



4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such persons involvement in any type of business or securities activities.



No.



C. Beneficial Owners



The following table sets forth, as of October 31, 2006, certain information with respect to the Company's equity securities owned on record or beneficially by (i) each Officer and Director of the Company; (ii) each person who owns beneficially more than five percent (5%) of each class of the Company's outstanding equity securities; and (iii) all Directors and Executive Officers as a group.



Common Stock





Title of Class




Name and Address

of Beneficial Owner (1)




Amount and Nature of

Beneficial Ownership




Percent

of Class (2)

Common

Stock


Keith A. Houser



125,000,000 Shares

Trustee


49.3%















Common

Stock


Charles R. Crane



23,000,000 Shares

Trustee


9.1%













Common

Stock


Kim Peralta Jacobs



6,517,000 Shares

Trustee


2.5%













Common

Stock


Executive Officers and

Directors as a Group

(3 Persons)



154,517,000 Shares


60.9%

__________

(1) Unless otherwise noted, the address of each beneficial owner is in c/o The Company.



(2) Based on 253 million shares outstanding as of October 31, 2006, 35 million shares of common stock are subject to options or warrants currently exercisable, or exercisable within 60 days, are deemed outstanding for purposes of computing the percentage of the person holding such options or warrants, but are not deemed outstanding for purposes of computing the percentage of any other person.



D. Disclosure of Certain Relationships



Approximately 60.9% of our outstanding shares of common stock are held by BioTech Medics Investment Unit Trust, of which Keith A. Houser, Chairman of the Board and Chief Executive Officer, Charles R. Crane, our President and Director, and Kim Jacobs, our Secretary/Treasurer and Director are beneficiaries.



Item 12. Issuers Most Recent Balance Sheet and Profit and Loss and Retained Earnings Statements:



Our unaudited financial statements as of the quarter plus one month ended October 31, 2006, are enclosed herewith. Our CPA has not completed review of these statements; however, the CPA has been instructed to complete the review as soon as possible.



Item 13. Similar Financial Information for Such Part of the Two Preceding Fiscal Years as the Issuer or its Predecessor Has Been in Existence:



Our unaudited financial statements as of the end of the last two fiscal years ended December 31, 2005, and 2004, are enclosed herewith. The current management and board of directors were not in control of the Company during 11 months of 2004. Therefore, 2004 is not a reflection of current management and the Board of Directors leadership.



Item 14. Whether Quotation is Being Submitted or Published Directly or Indirectly on Behalf of Issuer, or any Director, Officer, or any Person, Directly or Indirectly the Beneficial Owner of More Than Ten Percent (10%) of the Outstanding Shares of the Issuers Equity Securities, and, if so, the Name of Such Person, and Basis for any Exemption under the Federal Securities Laws for any Sale of Such Securities on Behalf of Such Person:



To the best of managements knowledge, no quotations are being submitted by any broker or dealer on behalf of the Issuer or any director, officer, or ten percent (10%) shareholders.



All information contained herein is subject to change, modification and/or re-vision without notice. However, issuer will notify Pinksheets of any material changes.

Dated this 6th day of November 2006, at Carson City, Nevada.





BIOTECH MEDICS, INC.



Authorized Electronic Signature

_______________________________

By: Keith A. Houser

Its: Chief Executive Officer





BioTech Medics, Inc.

Pinksheets: BTMD.PK

Unaudited Balance Sheet

January 1, 2006 through October 31, 2006









ASSETS



Cash $ 122,099

Fixed Assets 85,000

Other Assets 3,362,900



TOTAL ASSETS $ 3,569,999





LIABILITIES



Accounts Payable $ 81,635

Current Liabilities 2,305,876

Long Term Liabilities 120,000



TOTAL LIABILITIES $ 2,513,303





EQUITY $ 1,056,696





TOTAL LIABILITIES & EQUITY $ 3,569,999































BioTech Medics, Inc.

COMBINED INCOME STATEMENT (UNAUDITED)

JANUARY 1, 2006 THROUGH OCTOBER 31, 2006







ORDINARY INCOME & EXPENSE





INCOME $ 408,275

COST OF GOODS SOLD ( 30,025)



GROSS PROFIT $ 378,250







EXPENSES



ADVERTISING $ 4,223

LEGAL & PROFESSIONAL 70,969

RENT & EQUIPMENT LEASES 45,210

MEDICAL CENTER WAGES & EXP 269,962

OFFICERS DEFERRED SALARY 490,000

RESEARCH & DEVELOPMENT 20,500

UNCATEGORIZED EXPENSES 91,574



TOTAL EXPENSES $ 992,438







NET INCOME (OR LOSS) ( 614,138)



























BioTech Medics, Inc.

Pinksheets: BTMD.PK

Unaudited Balance Sheet

FOR THE CALENDAR YEAR 2005









ASSETS



Cash $ 95,617

Fixed Assets 85,000

Other Assets 3,340,000



TOTAL ASSETS $ 3,520,617





LIABILITIES



Accounts Payable $ 61,035

Current Liabilities 2,305,876

Long Term Liabilities 80,000



TOTAL LIABILITIES $ 2,446,911





EQUITY $ 1,073,706





TOTAL LIABILITIES & EQUITY $ 3,520,617































BioTech Medics, Inc., a Nevada corporation (Symbol: BTMD)




(Formerly known as Corbel Holdings, Inc. [ Symbol: CBLH] )




Unaudited Balance Sheet Ending December 7, 2004
























ASSETS

































Cash











$ 0





















Buildings & Depreciable Assets





$ 460,000










(less accum. Depreciation)





$ (29,340)





$ 0










$ 430,660










Land (net of amortization)





115,000





$ 0





















Intangible Assets (amortizable)





$ 4,274
















$ (534)





$ 0










$ 3,740


-------------------




TOTAL ASSETS





$ 549,400





$ 0





















LIABILITIES & SHAREHOLDERS EQUITY






























Accounts Payable





$ 10,500





$ 0





















Mortgages, Notes payable in less than 1 yr





$ 8,152





$ 0





















Loans from Shareholders





$ 152,690





$ 0





















Mortgages, Notes payable in 1 yr or more





$ 397,067





$ 0





















Capital Stock (common)





$ 29,313





$ 98,013




Additional Paid-in Capital





$ 180,116





$ 2,369,917





















Retained Earnings





$ ( 228,438)





$ (2,467,930)
















-------------------




TOTAL LIABILITIES & SHAREHOLDERS EQUITY $ 549,400





$ 0


















THESE FIGURES WERE PREPARED BY THE CPA FIRM OF BAGELL, JOSEPHS & CO, LLP, GIBBSBORO, NJ





END OF FILING

============================================================================

Cybersmearers

Quote by Thomas J. Donovan, B.A., Harvard University, magna cum laude,

1975; J.D., University of Pennsylvania, 1978:

"Many public company discussion boards sink into a routine of rumors and recriminations. Occasionally, some of these rumors are serious enough to affect the stock price. The poster may be attempting to take advantage of these stock swings on the basis of his or her trading position. Beyond the short term effect on stock prices, some postings may accuse management of assorted misdeeds or criminal acts. They may disparage the business or products of the company."

An important message from Keith Houser, CEO of BioTech Medics:

We believe it appropriate to pass information on to our site visitors regarding Cybersmearers or "bashers". This company has been the victim of Cybersmearers on a few "message boards". The Company is taking appropriate action to legally counter any false and/or misleading posts.

Here is proof of what attorney Donovan has stated are acts by bashers:

04 Jan 2005, 11:02 AM Post: "JUST SHORTED THIS PUPPY"

Above the public bulletin board notice is posted that a basher is shorting BTMD stock.

04 Jan 2005, 01:01 PM Post: Has BTMD trading been halted? Hmmmmmmmm

Above we have another basher post a disparaging FALSE statement hoping the stock

will fall to fill the short and make a profit for the basher (or bashers) who are shorting.

Thank God the basher's tactics did not work this day, the stock went up, not down.

UPDATE: NEW BASHING AND SHORTING OF BTMD STOCK 01/26/2005:

26 Jan 2005, 12:19 PM EST POST: "SHORT THIS POOCH"

If you happen to come across one of these Cybersmearers,

please email us at: cybercriminals@biotechmedics.com

Try to copy the details or give us the web site. If you have a question regarding a Cybersmear comment, you are welcome to call or email us for the truth.

How Cybersmearers Amplify Their Message **

The perpetrators of Cybersmear (or what is referred to as Internet Terrorism), are prone to predictable patterns. Most common among these is the strategy of amplifying a complaint or several accusations in an attempt to lend credibility. This is done largely through what we call proliferation and amplification.

The goal of an Internet Terrorist is to inflict harm on the target company or individual. This is done through what must seem to be credible information that also must appear to be large and prevalent.

Here are the consistent tactics of Cybersmearers on-line:

Anonymous postings on scattered chat rooms and/or bulletin boards.
Look for postings chronicling the injustices of the accused company in what appears to be detailed bashing or techno-discussion. Look for (amateur, unlicensed) interpretation and conclusions.
. Look for information or quotes taken out of context from the accused, or represented in very small segments as to be presented in a more misleading manner.
With very few exceptions these basher will claim a concern for innocent victims or the unsuspecting customer.
With few exceptions these bashers will claim a neutral stance, but will solicit either comments or emails which will predominate in the direction of the Smear (this is key to identifying a smear. True neutral discussions open to the public generally occur with both positive and negative viewpoints equally represented. If the balance is tilted too far in one direction, it is the fingerprint of a smear, and the posted comments can safely be considered false).
It is common for all of the comments to be anonymously posted by the perpetrator(s) to create the sense of unified outrage or a virtual stampede of individuals who agree or surprising public outrage (all actual quotes).
Further, perpetrators will anonymously post slightly varying opinions (all in the direction of the smear, of course), so a discussion can occur on finer points of the smear, all the while creating the impression of a larger complaint field.
Among what is usually a small circle of smear perpetrators (generally ten or less individuals behind the largest and most famous smears), automatic posting notifications are sent out whenever one individual places new content on the Internet. This allows the others to rush to the scene with their anonymous postings, again, providing amplification and a false impression of the scope of the complaint.
The band of smear perpetrators will carefully interlink their sites (to a controlled result, over linking is punished by search engines) so that their websites receive high ranking in search result pages.
Key words, many times the company or personal name of the accused, will be used in the bashing of titles, body of text, and Meta tags so that someone searching for the accused will automatically find the Cybersmear websites. In this way, the smear is made known to those searching for the accused company or individual.
The smearers strategy is to accomplish the following in the mind of the reader: I didnt realize all of this about (company or person). I wouldnt normally believe it, but there is so much of it on the Internet. If its that prevalent, it must have some truth to it.

Cybersmear perpetrators have simply followed the historical basis of telling lies successfully and applied it to the Internet.

Adolph Hitler said, The longer you tell a lie, the more people will believe it.

Our Cybersmear enemies know this strategy well, and they will use the above tactics of amplification and proliferation to achieve it.



** Portions of this information were contributed by

http://cybersmear.typepad.com/cybersmear_blog/2004/08/how_cybersmeare.html


















Home Co History Management Advisory Board Laser Contact Us Laser FAQS Testimonies Investor Info Mission Site Terms Arthritis News! Litigation HQ Offices Medical Clinics SHBAN SOLUTION New Press Releases Old Press Releases L I N K S

IMO

Email this page to a friend


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 1550 []
Previous Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...